Samsung Bioepis Co., Ltd.
Clinical trials sponsored by Samsung Bioepis Co., Ltd., explained in plain language.
A biopharmaceutical company developing and manufacturing biosimilars.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a copycat drug match the real thing? a trial puts ixekizumab to the test Results expected Jun 2027 (estimated)
-
Cheaper keytruda? new biosimilar SB27 tested in lung cancer
Disease control OngoingThis phase 3 trial tests whether SB27, a proposed biosimilar to the cancer drug Keytruda, works as well as the original in people with advanced non-squamous non-small cell lung cancer. About 555 participants will receive either SB27 or Keytruda plus chemotherapy every 3 weeks. Th…
Phase 3 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a cheaper keytruda copy work for lung cancer?
Disease control OngoingThis trial compares a biosimilar drug (SB27) to the standard cancer immunotherapy Keytruda in 163 people with stage II-IIIA non-small cell lung cancer who have already had surgery and chemotherapy. The main goal is to see if the body processes SB27 the same way as Keytruda. If su…
Phase 1 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC